Success Metrics

Completion Rate
0%(0/3)
Active Trials
0(0%)
Terminated
3(100%)

Phase Distribution

Ph phase_2
3
100%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Terminated3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

terminated3100%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_2

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

NCT03155932
terminatedphase_2

Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

NCT03072953
terminatedphase_2

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

NCT03139032

Clinical Trials (3)

Showing 3 of 3 trials
NCT03155932Phase 2

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Terminated
NCT03072953Phase 2

Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

Terminated
NCT03139032Phase 2

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

Terminated

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3